- Research article
- Open Access
Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
BMC Pharmacology volume 7, Article number: 8 (2007)
The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies.
Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with Kiapp values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar Kiapp values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S3 subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S2 subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3.
On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases.
Apoptosis is a major form of cell death, characterized by a series of apoptosis-specific morphological alterations and nucleosomal DNA fragmentation of genomic DNA [1–3]. Recent studies toward understanding of the apoptosis machinery have revealed the essential roles of a family of cysteine aspartyl proteases named caspases (for reviews, refs 4 and 5). To date, 14 caspases have been implicated in the apoptotic and inflammatic pathway cascades: Caspases-2, -3, -6, -7, -8, -9, and -10 are involved in the initiation and execution of apoptosis, whereas caspases-1, -4, and -5 participate in the activation of pro-inflammatory cytokines during inflammation [4–9]. Apoptotic caspases can be subdivided into initiator and executioner caspases. They are normally expressed as proenzymes that mature to their fully functional form through proteolytic cleavage [4–9]. Autoprocessing of initiator caspases (e.g. caspases-2, -8, -9, and -10) is facilitated by adaptor proteins, such as the Fas-associated death domain protein (FADD) and apoptosis protease activating factor-1 (Apaf-1). Executioner caspases (e.g. caspases-3, -6, and -7) can be activated following proteolytic processing by initiator caspases [10, 11]. Activated executioner caspases cleave a critical set of cellular proteins selectively and in a coordinated manner leading to cell death. More than 60 caspase substrates have been identified to date .
The caspase cascades in apoptosis maintain and amplify the original apoptotic stimuli, and their disregulations are involved as key factors in the development of a variety of diseases, including Alzheimers's disease , Parkinson's disease  and cancer . In particular, caspase-3 has been characterized as the major contributor to the process of apoptosis, and the phenotype of caspase-3 knockout mice suggests the necessity of the enzyme during brain development . Therefore, studies with peptide inhibitors of caspase-3 have helped to define a central role for the enzyme in apoptosis. So far, several peptide inhibitors of caspase-3 have been reported [17–20], some of which were effective in animal models of amyotrophic lateral sclerosis (ALS) , sepsis , and hypoxic-ischemic brain injury .
Among caspases, the structures of caspases-1, -2, -3, -7, -8, and -9 have been determined by X-ray crystallography [24–29]. The three-dimensional structures reveal that the active sites of all caspases contain positively charged S1 subsites that bind the negatively charged Asp in the P1 position on the substrates. Since the S1 subsites are highly conserved, all caspases cleave solely after aspartate residues [7, 24–29]. Recognition of at least four amino acids (P1–P4) in the cleavage sites is also a necessary requirement for efficient catalysis. The S2–S4 subsites on caspases vary significantly, resulting in varied substrate specificities for the P2–P4 positions, despite an absolute requirement for Asp in the P1 position [7, 24–29]. To define the peptide substrate specificities at the P2–P4 positions of caspases, a combinatorial approach using a positional scanning synthetic combinatorial library (PS-SCL) was taken. As a result, the optimal recognition sequence of peptide substrate for caspase-3 was shown to be DEVD . The sequence DEVD within poly(ADP-ribose) polymerase (PARP) is known to be recognized and cleaved by caspase-3 . This sequence has been applied to creating the peptide aldehyde inhibitor Ac-DEVD-CHO. However, Ac-DEVD-CHO inhibits not only caspase-3 activity, but also the activities of caspases-1, -6, -7, -8, -9, and -10 . To date, therefore, no tetrapeptide inhibitor selective for caspase-3 has yet to be identified.
It should be possible to derive the most selective and potent peptide inhibitor for each caspase from its comprehensive tetrapeptide library. In this regard, we recently developed a new strategy named the APF method for the computational design of peptides with high affinities for target proteins . This computational virtual screening method allows the rapid prediction of binding free energies between all peptides being tested and a target protein. Recently, we used this method to identify potent peptide inhibitors of caspase-3. Importantly, a novel specific peptide inhibitor, Ac-DNLD-CHO, was shown to have almost the same potent inhibitory activity against caspase-3 as the well-known Ac-DEVD-CHO. In this study, we investigated the structural and functional relevance to potency and selectivity of this rationally designed peptide by enzyme kinetic analyses, computational docking studies and site-directed mutagenesis analysis. The results identify the specific interaction of the P3 position (Asn) in DNLD with the S3 (Ser209) subsite on caspase-3 as the most important determinant of the selectivity of Ac-DNLD-CHO.
Potency and selectivity of Ac-DNLD-CHO against caspase-3
At present, three peptide inhibitors (aldehyde form) of caspase-3, Ac-DEVD-CHO, Ac-DQTD-CHO, and Ac-DMQD-CHO, are commercially available. Therefore, we compared the potency and selectivity of these peptide inhibitors with Ac-DNLD-CHO using human recombinant caspases-3, -7, -8, and -9. As shown Fig. 1A, Ac-DNLD-CHO inhibits caspase-3 (IC50 = 9.89 nM) with almost the same potency as Ac-DEVD-CHO (IC50 = 4.19 nM). The apparent Kiapp values for Ac-DNLD-CHO and Ac-DEVD-CHO are calculated to be 0.680 and 0.288 nM, respectively (Table 1). Ac-DEVD-CHO inhibits caspase-7 (Kiapp = 4.48 nM), -8 (Kiapp = 0.597 nM), and -9 (Kiapp = 1.35 nM) to similar extents. This observation is consistent with the previous report that Ac-DEVD-CHO inhibits caspases-3, -7, and -8 . In contrast, Ac-DNLD-CHO has very low inhibitory activity against caspases-8 and -9. Although Ac-DNLD-CHO inhibits caspase-7, the IC50 (245 nM) is one-order of magnitude higher than that of Ac-DEVD-CHO (IC50 = 19.7 nM). It is noteworthy that Ac-DNLD-CHO exhibits an approximate by 80-fold selectivity for caspase-3 over caspase-7 (Kiapp = 55.7 nM) (Table 1), although these caspases have very similar protein structures and substrate preferences .
Ac-DQTD-CHO inhibits caspases-3 (Kiapp = 1.27 nM) and -8 (Kiapp = 9.75 nM) weakly as compared to Ac-DEVD-CHO, and inhibits caspase-9 (Kiapp = 14.5 nM) and -7 (Kiapp = 21.8 nM) even more weakly (Fig. 1 and Table 1). These inhibition curves for Ac-DQTD-CHO are shifted about one order of magnitude lower than those of Ac-DEVD-CHO. On the other hand, Ac-DMQD-CHO inhibits caspase-3 weakly (IC50 = 193 nM), whereas it has little inhibitory effect on caspases-7, -8, and -9 even at concentrations up to about 200 nM (Fig. 1 and Table 1). The kinetic analyses show Ac-DNLD-CHO to have a potent and selective inhibitory activity against caspase-3, whereas Ac-DEVD-CHO potently inhibits all four caspases tested.
Abilities of caspases to cleave the fluorometric substrate of DNLD
To determine the potency and selectivity of the DNLD sequence against caspase-3, we compared substrate preferences between DNLD and DEVD among caspases. Currently, Ac-DEVD-MCA is used as the substrate for caspase-3 (DEVDase). Unfortunately, caspases-7, -8, and -9 are also able to cleave this substrate (Fig. 2), consistent with the previous observation  that although caspase-3 is the major source of cellular DEVDase activity in apoptotic cell extracts, other caspases are considered to contribute to the DEVDase activity. That is, DEVDase is not necessarily equivalent to the true activity of caspase-3. From these data, it is clear that using Ac-DEVD-MCA as a substrate makes it hard to measure precisely the activity of caspase-3 alone in crude cell extracts.
To probe the functional difference between DNLD and DEVD sequences, we synthesized Ac-DNLD-MCA and examined its preference as a substrate. As shown in Fig. 2A, Ac-DNLD-MCA is cleaved as efficiently by caspase-3 as Ac-DEVD-MCA. Importantly, Ac-DNLD-MCA is hardly cleaved by caspase-7 (Fig. 2B). Additionally, caspases-8 and -9 have no ability to cleave Ac-DNLD-MCA (Fig. 2C and 2D). This implies that using Ac-DNLD-MCA makes it possible to measure the sole activity of caspase-3 in cell extracts. Taken together, these data suggest that the recognition of the DNLD sequence among the caspases is selective to caspase-3.
Definition of active site residues of caspases
In order to understand the specificity of the sequence DNLD for caspase-3 in the structural aspects, we next sought to determine the amino acid residues composing the active sites of caspases. By inspecting the interactions of peptide/caspase complexes in their X-ray structures [24–29], we identified fifteen and fourteen residues in the active sites of caspases-2, -3, -6, -7 and -10, and caspases-8 and -9, respectively (Fig. 3A). The active site residues are located in segments on the linear sequences of caspases (Fig. 3A), and construct similar 3 dimensional pockets of the active sites (Fig. 3B). From these data, 4 subsites (S1, S2, S3, and S4) (Fig. 4A) can be assigned that indicate common structural positions in the active sites of all caspases (Fig. 4B).
The aligned active site residues in each caspase construct almost the same subsites. The difference is that the active site residues (ϒ in Fig. 3A) of caspases-3 (F256), -7 (F282), -6 (A269), -10 (S500) and -2 (F409) belonging to the S2–3 subsites are aligned at the same position in the sequences, while those of caspases-8 (Y365) and -9 (K292) are aligned at different positions (compare Fig. 3A and Fig. 4). However, the structural superposition of these caspases (Fig. 3B) reveals that these amino acids are located at the same position (S2–3) in the S2 subsites (Fig. 4). Previous work has also shown that caspase-8 has Y365 situated in roughly the same spatial position as F256 of caspase-3 . Thus, using the primary and tertiary structural information about caspases, we identified the amino acid residues important for substrate binding in the active sites of caspases as illustrated in Fig. 4 in a model of DEVD binding.
Evaluation of active site definition
Fig. 5 shows the plots of the free energies of binding calculated by AutoDock  and the experimentally observed Kiapp values summarized in Table 2. The best value obtained for Ac-DNLD-CHO is -12.99 kcal/mol (complex with caspase-3). Importantly, there are good correlations between all the calculated free energies of binding of Ac-DNLD-CHO to caspases-3, -7, -8 and -9, and their observed Kiapp values. The correlation coefficient of R = 0.75 obtained from the plots is an appropriate value, suggesting that the AutoDock program used here produces reliable binding modes, and that the definition of amino acid residues composing the active sites of caspases is adequate.
Phylogenetic analysis of the apoptotic caspases-2, -3, -6, -7, -8, -9, and -10 shows that executioner caspases (-3, -7, and -6) belong to the same subfamily and initiator caspases (-2, -8, -9, and -10) belong to other subfamilies, thus reflecting their functional roles (Fig. 6A). If our active site definition is adequate, a similar phylogenetic analysis against the active site residues defined above (Fig. 4B) would reflect their substrate specificities. The phylogenetic analysis of the active site residues was conducted by the NJ algorithm . Interestingly, the active site phylogeny is consistent with the substrate specificities of caspases (Fig. 6B). Nicholson and co-workers have clearly demonstrated that caspases are divided into three groups on the basis of substrate specificity analysis using a combinatorial approach: Group I enzymes (caspases-1, -4, and -5) prefer (W/Y)EHD↓ peptides; Group II enzymes (caspases-2, -3, and -7) prefer DEXD↓ peptides; Group III enzymes (caspases-6, -8, -9, and -10) prefer (I/L/V)EXD↓ peptides [30, 31]. As shown in Fig. 6B, caspases-3, -7, and -2 (Group II) are classified into together, and other caspases-6, -8, -9, and -10 (Group III) fall into other classes. It should be noted that caspase-2 belongs to the same class as caspases-3 and -7 in our active site phylogenetic analysis (Fig. 6B), although caspase-2 is suggested to be an initiator caspase (Fig. 6A). The results strongly support the validity of our active site definition as illustrated in Fig. 4B.
Evaluation of docking program for binding mode analysis
To elucidate the reason that Ac-DNLD-CHO is a potent and selective inhibitor for caspase-3 even though it has the same DXXD motif as Ac-DEVD-CHO, Ac-DQTD-CHO, and Ac-DMQD-CHO, computational docking studies were employed. We performed docking analysis using the AutoDock algorithm  to examine the binding modes of the peptide inhibitors at the active sites of caspases-3, -7, -8, and -9.
Among the above caspase inhibitors, a well-known Ac-DEVD-CHO was docked into the active sites of caspases, and then we measured how close the AutoDock can reproduce their complex structures of Ac-DEVD-CHO/caspase. Superpositions with the most minimized energies of docked Ac-DEVD-CHO in complexes of Ac-DEVD-CHO/caspases-3, -7, -8, and -9 yield root mean square distances (RMSDs) of 1.28 Å, 1.41 Å, 1.85 Å, and 1.46 Å, respectively (Table 2). Hence, AutoDock analysis is successful in reproducing the binding conformation of tetrapeptide inhibitors (aldehyde form). Furthermore, the results indicate that our docking procedures (energy minimization protocol and docking parameters) are reliable.
Selective binding mode of Ac-DNLD-CHO with caspase-3
To understand the binding mode of Ac-DNLD-CHO with caspase-3, Ac-DNLD-CHO was docked onto the active site of caspase-3 by the AutoDock program (Fig. 7A). The main-chain of Ac-DNLD-CHO forms hydrogen bonds at NH (Asn3) – O (Arg207), O (Asn3) – NH (Arg207), O (Leu2) – HH1 (Arg207), and NH (Asp1) – O (Ser205) in the S1 and S3 subsites, respectively (Table 3). Asp in the P4 position of Ac-DNLD-CHO donates hydrogen bonds to the Asp208, Trp214, and Phe250, and Asp in the P1 position interacts with Arg64. All of these interactions are observed in the complex of Ac-DEVD-CHO/caspase-3 although the hydrogen bonding distances and angles are slightly different (Table 3, Fig. 7B). It should be noted that Asn (P3) and Leu (P2) in Ac-DNLD-CHO have characteristic interaction patterns with caspase-3; the HD of Asn (P3) forms a direct hydrogen bond with OG of Ser209 (S3–4 subsite) and does not interact with Arg207 (S3-3 subsite), while Leu in the P2 position forms tight hydrophobic contacts with Trp206, Tyr204, and Phe256 in the S2 subsite of caspase-3. Meanwhile, the Glu in the P3 position of Ac-DEVD-CHO forms a direct interaction with Arg207 but not Ser209, although water-mediated interactions with Ser209 and/or Ser65 may exist (compare 7A and 7B, see Additional file 1)
Importantly, the S3–4 subsites of caspases-7, -8, and -9 have a conserved Pro residue (Fig. 4A). Consequently, a hydrogen bond between Asn (P3) in Ac-DNLD-CHO and the S3–4 subsite (Pro) of caspases-7, -8, and -9 can not be formed (Fig. 8, 1st. column). Furthermore, in the hydrophobic S2 subsites of caspases-8 (Val410, Tyr412, and Tyr365) and -9 (Val352, Trp354, Lys292), Leu (P2) of Ac-DNLD-CHO is difficult to be accepted (Fig. 8). In contrast, since the Arg at the S3-3 subsites is conserved in all caspase family proteins (Fig. 4A), the interactions of Glu (P3) of Ac-DEVD-CHO with the S3-3 subsites are considered to decrease the selectivity while they increase the binding affinities of Ac-DEVD-CHO (Fig. 8, 2nd. column). The hydrophobic contacts between Val (P2) of Ac-DEVD-CHO and the S2 subsites are probably weaker than those between Leu (P2) of Ac-DNLD-CHO and the S2 subsites (Fig. 8). This prediction is supported by comparisons of the changes in Accessible Surface Area (ΔASA) between Leu (P2) and Val (P2), which are calculated to be 145 and 113 Å 2, respectively (Table 3). Because it is known that there is good correlation between the amount of nonpolar surface of higher ΔASA and hydrophobic interactions , the ΔASA of Leu (P2) of Ac-DNLD-CHO may bear to the potent binding affinity through the hydrophobic effect.
Alanine replacement analysis for specific recognition of DNLD by caspase-3
The above computational docking experiments suggest that the specific recognition of DNLD sequence by caspase-3 is attributable to the notable hydrogen bond between Asn (P3) and Ser209 (S3–4 subsite).
To prove the significance of Ser209 in the interaction of the substrate Asn, the caspase-3 residue Ser209 was replaced with alanine by site-directed mutagenesis and the effect on recognition of DNLD was determined using MCA-fused peptide substrates. The substituted (S209A) and wild-type caspase-3 (active forms) were generated by coexpression of HA-p17 and HA-p12 subunits in in vitro translation system (Fig. 7E). The mutant caspase-3 cleaved Ac-DEVD-MCA as efficient as the wild-type. In contrast, the substitution (S209A) resulted in greater than 60% loss of cleavage activity on Ac-DNLD-MCA (compare Fig. 7C and 7D). These results strongly support the computational prediction that the specific interaction of DNLD with caspase-3 is attributable to the hydrogen bond between Asn (P3) and Ser209 in the S3–4 subsite.
Specific interaction of Ac-DNLD-CHO with caspase-3
To examine the specificity of Ac-DNLD-CHO for caspase-3, the binding mode was further compared with Ac-DQTD-CHO and Ac-DMQD-CHO. Ac-DQTD-CHO, which inhibits caspases-3, -7, -8, and -9 activities with Kiapp values of 1.27 nM, 21.8 nM, 9.75 nM, and 14.5 nM, respectively (Table 1), has a similar selectivity for these caspases as Ac-DEVD-CHO, and its potency is one-order of magnitude lower than that of Ac-DEVD-CHO (Fig. 1). The reasons for the poor selectivity of Ac-DQTD-CHO as compared with Ac-DNLD-CHO may be due to the formation of hydrogen bonds between Gln (P3) with the Arg207 (caspase-3), Asn88 (caspase-7), Arg258 (caspase-8), or Arg355 (caspase-9) as in the case of Ac-DEVD-CHO, and weak hydrophobic contacts with the S2 subsites of all caspases (Fig. 8, 3rd. column).
On the other hand, Ac-DMQD-CHO, which inhibits the activities of caspases-3, -7, -8, and -9 with Kiapp values of 13.3 nM, >200 nM, >200 nM, and >200 nM, respectively (Table 1), has unique selectivity for caspase-3, but with low potency for all. This may be attributed to a lack of interaction between Gln (P2) and the S2 subsite (Fig. 8, 4th. column). Meanwhile, no side-chain hydrogen bonds between Met (P3) of Ac-DMQD-CHO and the S3-3 subsites of caspases-8, and -9 are formed. In the cases of caspases-3 and -7, the formation of hydrogen bonds between Met (P3) and the Arg (Arg207 for caspase-3 and Arg233 for caspase-7) in the S3-3 subsites is possible (Fig. 8, 4th. column). These results strongly support the specificity of Ac-DNLD-CHO for caspase-3. The biding modes used in this analysis are available in additional data file [see Additional file 1].
Ac-DNLD-CHO is the first reported example of a novel potent peptide inhibitor of caspase-3 . The sequence was rationally designed by the structure-based computational APF method, and is so far not known in any natural caspase substrate. Furthermore, Ac-DNLD-CHO has been shown to inhibit caspase-3 as potently as Ac-DEVD-CHO, a well-known caspase-3 inhibitor. These observations suggest that the APF method is useful to design effective peptides with high binding affinities for target proteins. In the present study, we examined the specificity of Ac-DNLD-CHO for caspase-3 by inhibition kinetics analysis, computational docking studies and site-directed mutagenesis. In our in vitro assay system, Ac-DNLD-CHO inhibits caspase-3 (Kiapp = 0.68 nM) more selectively than caspases-7, -8, and -9 (Kiapp = 55.7, >200, and >200 nM, respectively). These observed Kiapp values correlate well with the calculated free energies of binding (ΔGcalc) by AutoDock between Ac-DNLD-CHO and caspases-3, -7, -8, and -9 (ΔGcalc = -12.99, -11.99, -10.78, and -9.98 kcal/mol, respectively). In plots of the calculated ΔGcalc values and experimentally observed Kiapp values, a correlation coefficient of R = 0.75 was obtained. This implies that the AutoDock produces reliable binding conformations of tetrapeptides on caspase molecules and that it is suitable for the analysis of the binding modes of tetrapeptide/caspase complexes.
The docking studies data reveal the notable characteristics of Ac-DNLD-CHO binding to caspase-3 to be the hydrogen bonds between Asn (P3 position) and Ser209 in the S3–4 subsite of caspase-3, and the tightly hydrophobic contacts between Leu in the P2 position and the S2 subsite composed of three aromatic amino acids, Tyr204, Trp206, and Phe256. In the S3 subsite of caspase-3, Ser209 (S3–4) is highly preferred for the interaction with Asn (P3), although other residues such as Arg can be accommodated, as observed in the case of caspase-8 (Fig. 8, 1st. column). A weak side chain-side chain hydrogen bond is formed between Arg258 (S3-1) of caspase-8 and Asn (P3) rather than that formed between Ser209 (S3–4) of caspase-3 and Asn (P3). Hence, Asn in Ac-DNLD-CHO is the only peptide residue involved in a side-chain-specific hydrogen bond with Ser209 (S3–4) in the caspase-3 molecule.
The alignment of active site residues also supports these characteristic, and provides the information for speculating the binding ability of Ac-DNLD-CHO to other apoptotic caspases. The S3–4 subsites of caspases show considerable diversity in their amino acids and in their interaction with Asn (P3) of Ac-DNLD-CHO, which is only possible for caspase-3. In caspase-8, Asn (P3) is able to interact with Arg258 (S3-1) only when the conformation of the main-chain backborn is considerably changed (Fig. 8, 1st. column). Arg207, Arg233, Arg 413, and Arg355 (S3-3 subsites) in caspases-3, -7, -8, and -9, respectively, do not interact with Asn (P3). Meanwhile, the Glu in the P3 position of Ac-DEVD-CHO binds to Arg207 (S3-3 subsite) in caspase-3. The S3-3 subsites of caspases-3, -7, -8, and -9, however, are also conserved as Arg residues. Therefore, Glu (P3) probably interacts tightly with Arg (S3-3 subsites) in all of the caspases. Obviously, substitution of Glu with Asn in the P3 position results in a substantial increase in the selectivity of DNLD for caspase-3.
On the other hand, amino acid residues in the P2 positions of peptides such as Leu and Val are highly preferred in the hydrophobic pockets in S2 subsites except for caspases-8 and -9, as illustrated in Fig. 8. Furthermore, the S2 subsites of caspases-3 and -7 have three hydrophobic aromatic residues. The structural analyse combined with the inhibitory activities suggest a critical role for the hydrophobic interactions between Leu (P2) in Ac-DNLD-CHO and the S2 subsite of caspase-3, since the ΔASA of Leu (P2) is wider than Val (P2) of Ac-DEVD-CHO (Table 3). Furthermore, although the docking information obtained by the comparison of DNLD with DEVD is somewhat difficult to understand completely, the stereochemical configuration of the peptide is important for both binding and inhibitory activity, while the loss of hydrogen bonds and hydrophobic interactions are critical.
The specific inhibitory activity of Ac-DNLD-CHO against caspase-3 is also confirmed by the comparison of both inhibitory activities and binding modes with commercially available caspase-3 peptide inhibitors, Ac-DQTD-CHO and Ac-DMQD-CHO (Fig. 8). The Gln (P3 position) side chain of Ac-DQTD-CHO can make contact with Args in the S3-3 subsites of caspases-3, -7, -8, and -9. The Thr in the P2 position interacts with hydrophobic pockets in the S2 subsites in all caspases. Hence, Ac-DQTD-CHO shows less selectivity and a lower inhibitory activity than Ac-DNLD-CHO. On the other hand, for Ac-DMQD-CHO, the Met substitution in the P3 position, which might reduce its ability to form hydrogen bonds with Arg in S3-3 subsites of caspases-3 and -7, resulting in a substantial decrease in inhibitory activity (Table 1). The substitution Leu or Val by Gln in the P2 position results in a complete lack of interaction, thereby drastically decreasing the inhibitory activity. On the basis of these docking studies, the specific inhibitory activity of Ac-DNLD-CHO on caspase-3 is strongly suggested to be due to the selective hydrogen bond between Asn (P3) and Ser209 in the S3–4 subsite, and the tightly hydrophobic contacts of Leu (P2) with the aromatic amino acids Tyr204, Trp206, and Phe256 in the S2 subsite.
Furthermore, we performed critical examinations of the sequence specificity of DNLD using fluorogenic MCA-peptide substrates, since in general, recognition of peptide sequence is detected more stringently in substrates than inhibitors. As expected, the fluorogenic substrate Ac-DNLD-MCA exhibited high selectivity for caspase-3 over caspases-7, -8, and -9. This implies that Ac-DNLD-MCA is useful for the precise measurement of the activity of caspase-3 in crude apoptotic cell extracts. In site-directed mutagenesis studies, the substituted (S209A) caspase-3 considerably decreased the ability to cleave Ac-DNLD-MCA (Fig. 7C). This is consistent with the computationally predicted binding mode of Ac-DNLD-CHO on caspase-3 (Fig. 7A). Obviously, the hydrogen bond between the caspase-3 residue Ser209 and the substrate Asn (N) plays a critical role in the specificity of the peptide.
Recently, to monitor the time course of caspase-3 activation during apoptosis at the cellular level, an expressed fusion protein containing cyan fluorescent protein (CFP) linked by a short peptide possessing the caspase-3 cleavage sequence, DEVD, to yellow fluorescent protein (YFP) (i.e. CFP-DEVD-YFP) has been utilized . The protein undergoes fluorescence resonance energy transfer (FRET) between CFP and YFP. When caspase-3 is activated, the DEVD sequence is cleaved and FRET is reduced . By using the DNLD sequence, a more precise measurement is possible.
Previous studies have indicated that peptide-based caspase inhibitors are effective in animal models of ALS , sepsis , and hypoxic-ischemic brain injury . Some inhibitors, however, have poor whole cell activity due to limited cell permeability . In this study, although the in vivo use of Ac-DNLD-CHO was not performed, the activity would be enhanced by modifying the DNLD sequence with benzylcarboxy, methyl ester, and fluoromethyl ketone (FMK) (i.e. Z-D(OMe)NLD(OMe)-FMK) or protein transduction domains (PTDs), such as the TAT protein , Antennapedia homeodomain , or arginine-rich peptides  (i.e. PTD+Linker+DNLD-CHO). Furthermore, many peptide-mimetic caspase-3 inhibitors have been prepared based on the DEVD tetrapeptide. [38, 42, 43]. As has been suggested previously , the optimization of a binding peptide sequence for a target protein, such as DNLD, includes obtaining sufficient information about its subsequent conversion to small molecular non-peptidic compounds. The DNLD tetrapeptide characterized here, with a molecular mass of about 500, is within reach of small molecule design and can serve as a minimal model for a caspase specific inhibitor. Therefore, the optimized peptide-based design of small molecule mimetics would be expected to be possible by using the configuration with the lowest ΔG. In developing non-peptidic caspase-3-specific inhibitors, the DNLD tetrapeptide provides a valuable starting point for the design of specific peptide-mimetics and their optimization. For example, a unique side chain containing an amide is present at the P3 position of DNLD, suggesting that this is a critical target region in the design of caspase-3-specific small molecules and potential therapeutic agents.
On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The binding site for DNLD comprises the same active pockets of caspase-3 that are known to kind other inhibitory peptides such as DEVD, DQTD, and DMQD. The substituted residues Asn and Leu in the P3 and P2 positions, respectively, play important roles in both the selectivity and potency for caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Ac-DNLD-MCA could also be useful in determining whether caspase-3 acts in cells that respond to various apoptotic stimuli such as drugs and viruses. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases.
Ac-DNLD-CHO and Ac-DNLD-MCA were synthesized by Peptide Institute, Inc (Osaka, Japan). Ac-DEVD-CHO, Ac-DQTD-CHO, Ac-DMQD-CHO, Ac-DEVD-MCA, Ac-IETD-MCA, and Ac-LEHD-MCA were purchased from Peptide Institute, Inc. Recombinant human caspases-3, -7, -8, and -9 were from Calbiochem.
Caspase assay and inhibition
The activities of caspases-3 and -7 were measured using Ac-DEVD-MCA as the substrate. The activities of caspases-8 and -9 were measured using Ac-IETD-MCA and Ac-LEHD-MCA, respectively. To compare the inhibitory potencies of Ac-DNLD-CHO, Ac-DEVD-CHO, Ac-DQTD-CHO, and Ac-DMQD-CHO against caspases-3, -7, -8, and -9, one unit (the amount of enzyme that cleaves 1 nmol of the substrate sequence per hr) of each active recombinant human caspase was incubated with various concentrations of a peptide inhibitor in assay buffer (100 mM NaCl, 50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% glycerol, and 0.1% CHAPS, pH 7.4) at 37°C for 30 min with shaking in a 96-well assay plate (CORNING). Then, caspase substrate was added to each well to a final concentration of 200 μM and the liberation of MCA was monitored continuously at 37°C using a 96-well plate reader Wallace 1420 ARVOsx (PerkinElmer) with an excitation wavelength of 390 nm and an emission wavelength of 460 nm.
Ac-DNLD-MCA and Ac-DEVD-MCA cleavage assay
To characterize the potency and selectivity of Ac-DNLD-MCA for caspases-3, -7, -8, and -9, in vitro caspase activity assays were performed. One unit (the amount of enzyme that cleaves 1 nmol of substrate per hr) of each active recombinant human caspase was added to a reaction mixture containing 200 μM Ac-DNLD-MCA or Ac-DEVD-MCA in assay buffer (100 mM NaCl, 50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% glycerol, and 0.1% CHAPS, pH 7.4). Then, the liberation of MCA was monitored continuously at 37°C using a 96-well plate reader Wallace 1420 ARVOsx (PerkinElmer) with an excitation wavelength of 390 nm and an emission wavelength of 460 nm.
Construction of expression vectors of HA tagged p17 or p12 subunits of caspase-3
Human cDNA fragments containing p17 or p12 subunits of caspase-3 were generated by PCR from Jurkat cells. The primers used were p17, 5'-TCTGGAATATCCCTGGACAA C-3' (sense) and 5'-TTAGTCTGTCTCAATGCCACAGTC-3' (antisense); p12,5'-AGTGGT GTTGATGATGACATG-3' (sense) and 5'-TTAGTGATAAAAATAGAGTTC-3' (antisense). The amino-terminus of p17 or p12 were tagged with the HA epitope by PCR using the primers, 5'-CTCGAGCCACCATGTACCCATAC-3' (sense) and 5'-AGCGTAGTCTGGGAC GTCGTATGGGTACAT (antisense). The amino-terminus of HA tag includes XhoI site, and the site flanking the coding sequence is shown in bold letter. The PCR products were then subcloned into pcDNA3 B (Invitrogen) at the EcoRV site. After confirming the sequences, the inserts were excised by XhoI digestion and recloned into the XhoI site of pURE4 (Post Genome Institute Co., Ltd.).
Site-directed mutagenesis of p12 subunit
Site-directed mutagenesis of p12 subunit (S209A) was introduced using PCR. The following primers were used for the preparation of the mutant, 5'-AGTGGTGTTGATGA TGACATG-3' (position 176–208, sense) and 5'-ATTTCGCCAAGAATAATAACC-3' (position 176–208, antisense); 5'-GCAAAGGATGGCTCCTGGTTCATC-3' (position 209–277, sense) and 5'-TTAGTGATAAAAATAGAGTTC-3' (position 209–277, antisense). The mutated site (Ser209→Ala) was shown in bold letter. After each fragments were amplified and ligated, they were tagged with HA and subcloned into pcDNA3 B (Invitrogen) at the EcoRV site. After comfirming the sequences, the inserts were excited by XhoI digestion and recloned into the XhoI site of pURE4 (Post Genome Institute Co., Ltd.)
Generation of active caspase-3
Active caspase-3 was generated by coexpression of HA-p17 and HA-p12 (wild type or mutant) subunits in vitro using PURESYSTEM classic II (Post Genome Institute Co., Ltd.) according to the manufacturer's instructions.
Western blot analysis
Two μl aliquots of proteins (wild type or mutant) were subjected to 15% SDS/polyacrylamide gel and transferred onto PVDF transfer-membranes. Blots were blocked in TBST [20 mM Tris-HCl (pH 8.0), 400 mM NaCl, and 0.05% (w/v) Triton X-100] containing 2.5% (w/v) BSA for 1.5 h and probed with anti-HA antibody (Bethyl Laboratories, Inc.). After the membrane were washed with TBST, retained antibody was detected with anti-rabbit IgG-alkaline phosphatase conjugate and a Prote Blot Western detection kit (Promega).
Construction of phylogenetic tree
The amino acid sequences of the seven full-length human caspases retrieved from the Swiss-Prot database (accession numbers: caspase-2, P42575; caspase-3, P42574; caspase-6, P55212; caspase-7, P55210; caspase-8, Q14790; caspase-9, P55211; caspase-10, Q92851) were aligned using the Clustal W multiple alignment program , and then adjusted manually. Multiple alignment using the BLOSUM matrix series , a gap opening penalty of 11.0, and a gap extension penalty of 0.05 were chosen for aligning the sequences. Based on the alignment, a phylogenetic tree was constructed by the neighbor-joining (NJ) algorithms . To establish a classification for the active sites of caspases, phylogenetic analysis of the active site residues was conducted by the NJ algorithm (exclude positions with gaps). Bootstrap analysis was performed on 1000 random samples and analyzed by the Clustal W . The NJ analyses were displayed using NJ plot .
Computational molecular modelling
Molecular visualization was carried out in a DS ViewerPro (Accelrys, Inc., San Diego, CA). The coordinates of caspases-3, -7, -8, and -9 were obtained from the Protein Data Bank (PDB) (codes 1PAU, 1F1J, 1F9E, and 1JXQ). Water was removed from the PDB files. The crystal structures of caspases-3, -7, -8, and -9 include coordinates of Ac-DEVD-CHO, Ac-DEVD-CHO, Z-DEVD-CHO, and Glu-Val-Dehydroxymethylaspartic acid, respectively, as inhibitors. Since it is known that Ac-DEVD-CHO potently inhibits the activities of caspases , we constructed the models of the Ac-DEVD-CHO/caspase complex. To construct the complex structure of caspase-8/Ac-DEVD-CHO, the benzyloxy-carbonyl group of Z-DEVD-CHO was displaced by the acetyl group on the DS ViewerPro. The complex structure of Ac-DEVD-CHO/caspase-9 was constructed by superposition with that of the Ac-DEVD-CHO/caspase-8. The superposition was performed using the McLaghlan algorithm  as implemented in the ProFit program . The geometries of these complex structures were subsequently optimized using the GROMACS program [49, 50]. The coordinate of Ac-DEVD-CHO was converted to a GROMACS topology file by the Dundee PRODRG2 Server . Energy minimizations of the complex structures using a GROMACS forcefield were performed with the steepest descent algorithm.
Computational molecular docking
Molecular docking was carried out using AutoDock3.0  on a COMPAQ Alphastation DS20E (double 833 MHz processors and 1024 MB of memory). The binding free energy scoring function in the AutoDock is based on an empirical function derived by linear regression analysis of a large set of diverse protein-ligand complexes with known inhibition constants. There are many successful examples of structures of protein-ligand systems studied by the AutoDock program [52, 53]. The docking energy grid (grid maps with 60 × 60 × 60 points, grid spacing 0.375 Å) was produced with the AutoGrid program . The inhibitor centers in the complex structures were positioned at the grid center. The Lamarckian Genetic Algorithm was utilized, and energy evaluations were set at 3 × 106. Each simulation was performed a total of 20 times. Other parameters were default values. The initial conformations of caspase-3 inhibitors, Ac-DNLD-CHO, Ac-DEVD-CHO, Ac-DQTD-CHO, and Ac-DMQD-CHO, were built using coordinates that replaced the side chains of the Ac-DEVD-CHO in the complex structures with the side chains of the inhibitors. Rotational bonds in the inhibitors were assigned with the program AutoTors . All torsions except the peptide bonds were unconstrained during the docking. Based on the docking data, the lowest-energy docking mode was used to analyze the potency and selectivity of the caspase-3 peptide inhibitors.
Arends MJ, Wyllie AH: Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol. 1991, 32: 223-254.
Ellis RE, Yuan JY, Horvitz HR: Mechanisms and functions of cell death. Annu Rev Cell Biol. 1991, 7: 663-698. 10.1146/annurev.cb.07.110191.003311.
Tanuma S: Molecular mechanics of apoptosis. Apoptosis in Normal Development and Cancer. Edited by: Sluyser M. 1996, London, Taylor & Francis, 39-59.
Denault JB, Salvesen GS: Caspases: keys in the ignition of cell death. Chem Rev. 2002, 102: 4489-5500. 10.1021/cr010183n.
Philchenkov A: Caspases: potential targets for regulating cell death. J Cell Mol Med. 2004, 8: 432-444. 10.1111/j.1582-4934.2004.tb00468.x.
Cohen GM: Caspases: the executioners of apoptosis. Biochem J. 1997, 326: 1-16.
Thornberry NA, Lazebnik Y: Caspases: enemies within. Science. 1998, 281: 1312-1316. 10.1126/science.281.5381.1312.
Wolf BB, Green DR: Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999, 274: 20049-20052. 10.1074/jbc.274.29.20049.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995, 376: 37-43. 10.1038/376037a0.
Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM: An induced proximity model for caspase-8 activation. J Biol Chem. 1998, 273: 2926-2930. 10.1074/jbc.273.5.2926.
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES: Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell. 1998, 1: 949-957. 10.1016/S1097-2765(00)80095-7.
Chang HY, Yang X: Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev. 2000, 64: 821-846. 10.1128/MMBR.64.4.821-846.2000.
Shimohama S: Apoptosis in Alzheimer's disease. Apoptosis. 2000, 5: 9-16. 10.1023/A:1009625323388.
Jordan J, Galindo MF, Cena V, Gonzalez-Garcia C: Cysteine proteinase and neurodegeneration. Rev Neurol. 2000, 31: 333-340.
Kaufmann SH, Gores GJ: Apoptosis in cancer: cause and cure. Bioessays. 2000, 22: 1007-1017. 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4.
Kuida K, Zheng TS, Na S, Kuan C, Yang D, Karasuyama H, Rakic P, Flavell RA: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 1996, 384: 368-372. 10.1038/384368a0.
Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD: Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem. 1997, 272: 26056-26061. 10.1074/jbc.272.41.26056.
Takahashi A, Hirata H, Yonehara S, Imai Y, Lee KK, Moyer RW, Turner PC, Mesner PW, Okazaki T, Sawai H, Kishi S, Yamamoto K, Okuma M, Sasada M: Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Oncogene. 1997, 14: 2741-2752. 10.1038/sj.onc.1201131.
Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M: Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998, 187: 587-600. 10.1084/jem.187.4.587.
Yang W, Guastella J, Huang JC, Wang Y, Zhang L, Xue D, Tran M, Woodward R, Kasibhatla S, Tseng B, Drewe J, Cai SX: MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol. 2003, 140: 402-412. 10.1038/sj.bjp.0705450.
Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM: Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000, 288: 335-339. 10.1126/science.288.5464.335.
Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 2000, 1: 496-501. 10.1038/82741.
Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, Holtzman DM: Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest. 1998, 101: 1992-1999.
Rano TA, Timkey T, Peterson EP, Rotonda J, Nicholson DW, Becker JW: A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). Chem Biol. 1997, 4: 149-55. 10.1016/S1074-5521(97)90258-1.
Schweizer A, Briand C, Grutter MG: Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J Biol Chem. 2003, 278: 42441-42447. 10.1074/jbc.M304895200.
Rotonda J, Nicholson DW, Fazil KM, Gallant M, Gareau Y, Labelle M, Peterson EP, Rasper DM, Ruel R, Vaillancourt JP, Thornberry NA, Becker JW: The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat Struct Biol. 1996, 3: 619-625. 10.1038/nsb0796-619.
Wei Y, Fox T, Chambers SP, Sintchak J, Coll JT, Golec JM, Swenson L, Wilson KP, Charifson PS: The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem Biol. 2000, 7: 423-432. 10.1016/S1074-5521(00)00123-X.
Blanchard H, Donepudi M, Tschopp M, Kodandapani L, Wu JC, Grutter MG: Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex. J Mol Biol. 2000, 302: 9-16. 10.1006/jmbi.2000.4041.
Renatus M, Stennicke HR, Scott FL, Liddington RC, Salvesen GS: Dimer formation drives the activation of the cell death protease caspase 9. Proc Natl Acad Sci USA. 2001, 98: 14250-14255. 10.1073/pnas.231465798.
Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997, 272: 17907-17911. 10.1074/jbc.272.29.17907.
Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA: Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem. 1998, 273: 32608-32613. 10.1074/jbc.273.49.32608.
Yoshimori A, Takasawa R, Tanuma S: A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score. BMC Pharmacol. 2004, 4: 7-10.1186/1471-2210-4-7.
Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y: Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J. 1997, 16: 2271-2281. 10.1093/emboj/16.9.2271.
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998, 19: 1639-1662. 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.
Saitou N, Nei M: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987, 4: 406-425.
Lavigne P, Bagu JR, Boyko R, Willard L, Holmes CF, Sykes BD: Structure-based thermodynamic analysis of the dissociation of protein phosphatase-1 catalytic subunit and microcystin-LR docked complexes. Protein Sci. 2000, 9: 252-264.
Tyas L, Brophy VA, Pope A, Rivett AJ, Tavare JM: Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep. 2000, 1: 266-270. 10.1093/embo-reports/kvd050.
Han Y, Giroux A, Grimm EL, Aspiotis R, Francoeur S, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt JP, Rasper DM, Tam J, Tawa P, Thornberry NA, Paterson EP, Garcia-Calvo M, Becker JW, Rotonda J, Nicholson DW, Zamboni RJ: Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors. Bioorg Med Chem Lett. 2004, 14: 805-808. 10.1016/j.bmcl.2003.10.064.
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999, 285: 1569-1572. 10.1126/science.285.5433.1569.
Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994, 269: 10444-10450.
Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y: Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001, 276: 5836-5840. 10.1074/jbc.M007540200.
Guo Z, Xian M, Zhang W, McGill A, Wang PG: N-nitrosoanilines: a new class of caspase-3 inhibitors. Bioorg Med Chem. 2001, 9: 99-106. 10.1016/S0968-0896(00)00222-4.
Becker JW, Rotonda J, Soisson SM, Aspiotis R, Bayly C, Francoeur S: Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis. J Med Chem. 2004, 47: 2466-2474. 10.1021/jm0305523.
Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22: 4673-4680. 10.1093/nar/22.22.4673.
Henikoff S, Henikoff JG: Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA. 1992, 89: 10915-10919. 10.1073/pnas.89.22.10915.
Perriere G, Gouy M: WWW-query: an on-line retrieval system for biological sequence banks. Biochimie. 1996, 78: 364-369. 10.1016/0300-9084(96)84768-7.
McLaghlan AD: Rapid comparison of protein structures. Acta Crystallographica. 1982, A38: 871-873.
Berendsen HJC, van der Spoel D, van Drunen R: GROMACS: A message-passing parallel molecular dynamics implementation. Comp Phys Comm. 1995, 91: 43-56. 10.1016/0010-4655(95)00042-E.
Lindahl E, Hess B, van der Spoel D: GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Mod. 2001, 7: 306-317.
Schuettelkopf AW, van Aalten DMF: PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica. 2004, 60 (Pt 8): 1355-1363.
Bartolucci C, Perola E, Pilger C, Fels G, Lamba D: Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins: Struct Funct Genet. 2001, 42 (2): 182-191. 10.1002/1097-0134(20010201)42:2<182::AID-PROT50>3.0.CO;2-1.
Jenkins JL, Shapiro R: Identification of small-molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking. Biochemistry. 2003, 42: 6674-6687. 10.1021/bi034164e.
Kabsch W, Sander C: Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983, 22: 2577-2637. 10.1002/bip.360221211.
We gratefully acknowledge the contributions of Dr. M. Tsunemi (Peptide Institute Inc.) to the preparation of the peptide substrate described in this study. This work was supported in part by a Grant-in-Aid for Scientific Research (No.18011009) from the Ministry of Education, Culture, Sport, Science and Technology of Japan.
AY participated in study design, and wrote the manuscript. AY and ST dealt with the computational aspects in the implementation. JS, NO and RT assisted with study design and performed caspase inhibition assays. SS, NO and TK performed the construction of expression vectors and site-directed mutagenesis. SIT conceived the study and participated in its design and coordination. All authors read and approved the final manuscript.
Electronic supplementary material
Additional File 1: ZIP file is a pdb format that is compressed. It contains caspase-3/peptide complexes (casp3_pep.pdb), caspase-7/peptide complexes (casp7_pep.pdb), caspase-8/peptide complexes (casp8_pep.pdb), and caspase-9/peptide complexes (casp9_pep.pdb). (ZIP 143 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Yoshimori, A., Sakai, J., Sunaga, S. et al. Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacol 7, 8 (2007). https://doi.org/10.1186/1471-2210-7-8
- Amyotrophic Lateral Sclerosis
- Fluorescence Resonance Energy Transfer
- Peptide Inhibitor
- Active Site Residue
- Hydrophobic Contact